申请人:Boehringer Ingelheim KG
公开号:US05532233A1
公开(公告)日:1996-07-02
The invention relates to new hetrazepines of general formula ##STR1## wherein A, Z, n, X, Y, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the meanings given in the specification. The new compounds are intended for use in treating pathological conditions and diseases in which PAF (platelet activating factor) is implicated.
该发明涉及一般式为##STR1##的新的噻唑啉类化合物,其中A、Z、n、X、Y、R.sub.1、R.sub.2、R.sub.3和R.sub.4的含义如规范中所述。这些新化合物可用于治疗PAF(血小板活化因子)参与的病理状况和疾病。